


This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims

1. *(currently amended)* A compound of Formula I:



wherein

Q is



R^1 , R^2 and R^3 are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;

X and Y ~~are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon~~

~~atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms, or X and Y~~, taken together, form ~~$-N=C(R^4)-C(R^5)=N-$, $-N=C(R^4)-C(R^6)=CH-$, $-N=C(R^4)-N=CH-$, $N=C(R^4)-O-$, $NH-C(R^7)=N$ or $NH-C(R^8)=CH-$~~ ;

R^4 and R^5 are, independently, hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R^6 is hydrogen or alkyl of 1 to 6 carbon atoms;

~~R^7 is hydrogen, halo, trifluoromethyl, pentafluoroethyl, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;~~

~~R^8 is hydrogen, halo, trifluoromethyl, pentafluoroethyl, or alkyl of 1 to 6 carbon atoms;~~

Z is O, S, or NR^9 , in which R^9 is hydrogen or alkyl of 1 to 6 carbon atoms;

n is an integer ~~0~~, 1, or 2;

m is an integer from 1 to ~~4~~ 2, ~~provided that $m+n \leq 4$ and that when $m=n=2$, and Q is b then X and Y are not $NH-C(R^8)=CH-$~~ ; and

p is an integer from 1 to ~~3~~ 2, provided that $p+n$ is 2 or 3;

or a pharmaceutically acceptable salt thereof.

2-3. (cancelled)

4. (original) A compound according to claim 1, wherein Z is NR^9 or a pharmaceutically acceptable salt thereof.

5. (currently amended) A compound according to claim 1, wherein n is ~~0 or~~ 1 or a pharmaceutically acceptable salt thereof.

6. (currently amended) A compound according to claim 1, wherein m is 1 ~~to 3~~ or a pharmaceutically acceptable salt thereof.

7. *(currently amended)* A compound according to claim 1, wherein p is 1 ~~or 2~~ or a pharmaceutically acceptable salt thereof.
8. *(original)* A compound according to claim 1, wherein R¹ is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
9. *(original)* A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
10. *(original)* A compound according to claim 1, wherein R⁴ and R⁵ are independently hydrogen, amino or alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
11. *(cancelled)*
12. *(currently amended)* A compound according to claim 1, wherein R⁶ is hydrogen or alkyl of 1 to 3 carbon atoms, Z is NR⁹ in which R⁹ is hydrogen or alkyl of 1 to 3 carbon atoms, ~~n is 0 or 1, m is 1 to 3 and p is 1 or 2~~ or a pharmaceutically acceptable salt thereof.
13. *(cancelled)*
14. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 15-16. *(cancelled)*

17. **(original)** A compound according to claim 1, wherein said compound is 2-[3-(1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
18. **(original)** A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 19-24. **(cancelled)**
25. **(original)** A compound according to claim 1, wherein said compound is 8-Methyl-2-[3-(5-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
26. **(original)** A compound according to claim 1, wherein said compound is the S enantiomer at the 2-aminomethyl-2,3-dihydro-1,4-benzodioxan moiety, substantially free of the R enantiomer of said compound.
- 27-29. **(cancelled)**
30. **(original)** A pharmaceutical composition, comprising:
an effective amount of a compound according to claim 1; and
a pharmaceutically acceptable carrier or excipient.
31. **(new)** A compound selected from the group consisting of:
2-[3-(5-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;
2-[3-(6-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;

2-({4-[(6-fluoro-1H-indol-1-yl)methyl]piperidin-1-yl})-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline;

2-({4-[(6-fluoro-1H-indol-1-yl)ethyl]piperidin-1-yl})-8-ethyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline;

1-[(1-{[8-methyl-2,3-dihydro[1,4]-dioxino[2,3-f]quinolin-2-yl]methyl})piperidin-4-yl]-1H-indole-6-carbonitrile;

2-[3-(6-fluoro-indol-1-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline;

2-{3-[2-(6-fluoro-indol-1-yl)-ethyl]-azetidin-1-ylmethyl}-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline;

1-{2-[1-(8-methyl-2,3-dihydro-[1,4]-dioxino[2,3-f]quinolin-2-ylmethyl)-azetidin-3-yl]-ethyl}-1H-indole-6-carbonitrile; and

pharmaceutically acceptable salts thereof.